Brain metastases are treated with surgery, radiotherapy, radiosurgery, and chemotherapy. In this review, recently published studies concerning different treatment strategies are presented with respect to solitary lesions, multiple metastases, and recurrent tumor growth. Selection criteria for the appropriate therapy are: control of the primary tumor, extent of extracerebral metastases, time interval between diagnosis of the primary tumor and the development of cerebral lesions, number of cerebral metastases, Karnofsky performance scale score, and age. Treatment approaches were evaluated with respect to median survival time and quality of life. A singular brain metastasis can be treated with surgery or with radiosurgery. Especially when the primary tumor is under control, there are few extracerebral lesions which are stable, the Karnofsky performance scale score is above 70, the lesion is larger than 3 cm in diameter and surgically accessible surgery is the treatment of choice. Postoperative adjuvant radiotherapy may delay relapse. Median survival time ranges between 10 to 18 months. Radiosurgery can be applied in lesions smaller than 3 cm in diameter and is the treatment of choice in lesions which are surgically not accessible. Multiple metastases are treated either by conventional radiotherapy, radiosurgery or surgery. Commonly, no more than 3 lesions are approached by either surgery or radiosurgery. Median survival time ranges between 6 to 9 months for both treatment concepts, but without therapy only is 4-6 weeks. According to the clinical and neurological condition of the patient, recurrent brain metastases can be treated by operation, reirradiation, or radiosurgery. The efficacy of chemotherapy depends on the chemosensitivity of the primary tumor and the ability to penetrate the blood-brain barrier. Long-term survivors with cancer disease encourage to perform active treatment strategies.
Introduction
Metastases to the brain occur in approximately 20-40% of all patients with carcinoma [1, 2] and comprise more than 30% of all brain tumors. Most cerebral metastases originate from primary lung tumors in 25%, from breast tumors in 21%, and from malignant melanoma in 10-15%. Autopsy data reveal that almost 70-90% of all patients with malignant melanoma develop cerebral lesions [3] .At the time of diagnosis more than 50% of the patients present with multiple lesions. There is a rising incidence of brain metastases, since advanced treatment strategies for extracerebral cancer prolong patient's survival and allow for development of brain metastases [4] . The goal in treating brain metastases is to eliminate the lifethreatening brain lesion that raises intracranial pressure and causes neurological deficits. Because brain metastases usually occur in the final stage of cancer, patients face reduced life expectancy. The median survival time without treatment ranges between 1 and 3 months [5, 6] . One of the major aims in treating these patients is to maintain or to improve their quality of life. Many treatment modalities have been applied during recent years. Prognostic factors have been evaluated that are associated with prolonged survival of patients. Here we review current treatment strategies according to recently published studies.
Diagnosis
Initial neurological symptoms of brain metastases include headaches, seizures or neurological deficits, e.g. hemiparesis, aphasia or hemianopsia. Mass effects lead to symptomatic elevated intracranial pressure with headaches, dizziness, vomiting, drowsiness and finally loss of consciousness. The diagnosis is usually made by cerebral computed tomography (CT) or magnetic resonance imaging (MRI). The typical diagnostic image on contrast-enhanced CT and T1-weighted MRI resembles a garland-like ring with central necrosis [7] . Very small lesions of less than 1 cm in diameter can be detected by T2-weighted MRI, demonstrating an edematous alteration of the parenchyma. MRI has to be applied on a routine basis in preoperative diagnosis of cerebral metastasis [8, 9] . Additional lesions may be detected that have not been visualized by CT scan. The sensitivity of MRI can be enhanced by high-dose application of contrast media [10, 11] , by the interval of time between i.v. injection of contrast media and imaging, and by the field strength of the scanner. The diagnosis of multiple cerebral metastases is crucial for further treatment decisions. Brain metastases of certain origin, e.g. from melanoma or hepatocellular carcinoma, tend to cause hemorrhage. The sudden onset of symptoms leads to differential diagnostic considerations, including spontaneous intracerebral hemorrhage without association with neoplastic disease. Murakami et al. [12] presented a series of 16 cases of hepatocellular carcinomas with brain metastases. Eight of these patients suffered from apoplexy-like symptoms; in 14 patients a hemorrhage had occurred. The authors point out the value of contrast-enhanced CT or MRI scan to differentiate between bleeding and tumorassociated bleeding.
In a prospective study by van de Pol [13] the question was raised whether primary staging of asymptomatic small-cell lung cancer patients should routinely include an MRI scan of the brain. The results of this study indicate that most patients develop clinical symptoms leading to the diagnosis of a cerebral lesion and that the routine scan of the brain rarely detects metastases at an early state. This study addresses the important question whether tumor staging in cancer patients has to include brain examination on a routine basis at least in primaries which tend to seed in the brain. Considering the development of metastases in functionally silent areas of the brain or as very small asymptomatic lesions, they might be undetected, although their detection will greatly influence treatment strategies (see below).
Microneurosurgical Therapy of a Single Brain Metastasis
In recent years, several studies have provided evidence that surgical excision of a brain metastasis optimizes quality of life and prolongs survival time. In a randomized prospective study by Patchell et al. [14] , the efficacy of surgery plus WBRT (Whole-Brain Radiation Therapy) versus radiotherapy alone was investigated. Only single brain metastases were included. The results of the study indicate that patients with a single brain metastasis who receive treatment with surgical resection plus radiotherapy live longer, have fewer recurrences and a better quality of life than those who have been treated only by radiotherapy. In 1992 Smalley et al. [15] evaluated 229 cancer patients with solitary cerebral lesions. All patients underwent craniotomy and part of them adjuvant WBRT. Prognostic factors for the survival time were the extent of systemic disease and gross total removal of cerebral lesions. Patients without systemic disease and total extirpation of brain metastasis had a median survival time of 1.3 years. Patients with systemic disease and subtotal tumor removal had a median survival of 5.3 months only. Adjuvant radiotherapy was associated with improved survival time. Delarive and de Tribolet [16] reported on 81 patients with brain metastases of different origin. All patients were treated by surgery and most of them received postoperative WBRT. The mean survival was 10.2 months. Ten patients survived more than 18 months, 1 patient more than 4 years. Long-term survivors (up to 10 years), even with brain metastases, are known from the literature [17, 18] . Prognostic factors were solitary brain lesions, no extracerebral tumor burden, control of the primary tumor, high Karnofsky performance score and total surgical resection of the cerebral lesion, in most cases accompanied by adjuvant radiotherapy. In 100 patients with colorectal cancer and brain metastases, the course of disease was studied with respect to single treatment strategies [5] . The different regimens included: surgery, radiotherapy alone, and steroids only. Most patients suffered from additional liver or lung metastases. The mean survival time for patients treated with steroids was 1 month, with radiotherapy alone 3 months, and with surgery alone 9 months. The authors found that the extent of extracerebral metastases did not necessarily lower life expectancy. However, a short interval between the development of the primary tumor and the ap-pearance of cerebral metastases worsened the prognosis significantly. Today, there is little doubt that single brain metastasis should be surgically removed whenever possible [4, 6, 19] . The operative technique of metastasis surgery is routine. Metastatic lesions are usually well circumscribed and show demarcation from the surrounding brain tissue. Small lesions can be approached by neuronavigation. Areas of functional importance can be preserved.
Microneurosurgical Treatment of Multiple Cerebral Metastases
Treatment of multiple brain metastases ranges from supportive care to conventional radiotherapy, chemotherapy, radiosurgery, and surgical management [20] [21] [22] [23] . There is no doubt that the development of multiple metastases implies a fatal prognosis. Surprisingly, patients with multiple metastases can be unimpaired, without significant neurological symptoms. These patients ask for active help. Conventional radiotherapy plays the most important role in treatment of multiple metastases [24] . However, the technical progress in recent years offers additional surgical and radiosurgical methods in treating these patients. In 1993 Bindal et al. [23] presented a review on 56 patients with multiple brain metastases who underwent surgery. In these patients all brain lesions were resected. The median survival time averaged about 14 months. Nussbaum et al. [25] published a study evaluating 729 patients with respect to histology, multiplicity, surgery, and survival. A total of 384 patients presented with a single and 345 with multiple brain metastases. The shortest time interval between diagnosis of the primary tumor and appearance of brain metastases was observed in non-small-cell lung cancer (NSCLC), being 3 months, and the longest in patients with breast cancer, being 53 months. The median survival for patients with a single metastasis treated by surgery was 11 months, and without surgery 3 months. In this study, surgery did not influence survival in patients with multiple metastases. Wronski et al. [26] reported on 231 patients with NSCLC. Subsequent to surgery, median survival time was 11 months. Patients with single metastases survived longer than those with multiple lesions (11.1 vs. 8 months). The conclusion from these studies and others [27, 28] demonstrates that patients with multiple cerebral lesions have a poor prognosis, but might still profit from surgical intervention. Again prognostic factors, e.g. systemic disease, the extent of extracerebral tumor burden, the amount of resection, the location of the lesions, and the Karnofsky performance scale score, are of great importance for the prognosis of the patient. Nowadays, operations in neurosurgery are routinely performed employing neuronavigation. With this method one can resect brain metastases at different sites after optimal planning of the approaches. Small targeted craniotomies are performed for the excision of brain lesions. During the last few years, in our department patients with multiple cerebral metastases (up to four lesions at different sites) have been operated on in one session ( fig. 1a-g ). The advantage for the patients was that all cerebral lesions were removed in one operation and the duration of hospitalization was no longer than for patients with single brain metastasis. One important criterion for this management was the preservation of quality of life, which should not be worsened by operative approaches.
Radiotherapy
Conventional WBRT alone is the most common treatment for patients with brain metastases. Median survival ranges from 3 to 6 months [24, 29, 30] . WBRT has been the mainstay of treatment since the 1950s. The standard treatment regimen is 10 × 3 Gy in 2 weeks, appropriate treatment varies depending on radiotherapeutic practices. Trials conducted by the Radiation Therapy Oncology Group (RTOG) indicate that doses ranging from 20 Gy over 1 week to 50 Gy over 4 weeks demonstrate no significant difference in neurological control of disease or length of survival, but that doses <20 Gy are less effective [30, 31] . Additional focal radiation to the tumor site has no better results than WBRT alone [32] . Large retrospective studies have shown that more than half of these patients treated with WBRT die from extracerebral tumor progression [2, 33] . Accelerated and hyperfractionated radiation schedules have been evaluated in several studies of the RTOG. In a randomized phase III study of accelerated hyperfractionation of patients with nonresected brain metastases (1.6 Gy b.i.d. to a total dose of 54.4 Gy vs. an accelerated fractionation of 30 Gy in 10 daily fractions) no treatment advantage could be found in the accelerated hyperfractionated group. Therefore, results reported from a previously RTOG phase I/II study [34] could not be confirmed [35] . It is still controversial as to whether adjuvant radiotherapy must follow after total extirpation of a solitary cerebral metastasis. Reasons advocating adjuvant radiotherapy are: 1. The incidence of local relapse may be increased in patients without adjuvant radiotherapy. 2. Small tumor cell clumps not visible by MRI at other sites can be destroyed by WBRT. Reasons for rejecting radiotherapy are: 1. Brain metastases are usually well defined and can be extirpated completely. 2. Radiotherapy can be preserved for recurrent tumor growth. Several investigators evaluated the efficacy of WBRT in addition to surgery versus WBRT alone [5, [14] [15] [16] [36] [37] [38] [39] . To date, the overall results of surgical treatment strategies plus adjuvant WBRT indicate that WBRT alone as treatment is inferior to the combined treatment [5, 14] . Whenever possible, surgical extirpation should be performed. Postoperative radiotherapy, although questionable, may result in a smaller portion of brain relapse and a higher percentage of patients remaining diseasefree [38] . The results of a prospective randomized study to evaluate the efficacy of surgery plus WBRT versus surgery alone are still pending. In multiple cerebral metastases WBRT alone or in combination with radiosurgery is the favorable treatment [24, [28] [29] [30] [31] [40] [41] [42] . In radiosensitive tumors, e.g. small-cell lung cancer [43] WBRT alone is the treatment of choice. Age was evaluated as an important factor for the prognosis of patients with cerebral metastasis. Nieder et al. [44] reported on 35 patients older than 70 years of age. The patients received 30 Gy WBRT and were treated with corticosteroids. Six patients received lower or higher total doses with 50.4 Gy at maximum. The median survival time of all patients who completed radiotherapy was 67 days. Patients with extracerebral metastases had a median survival of 31 days. The Karnofsky performance score was the most important prognostic factor. The poor results of this study again reveal the importance of age as prognostic factor. In some studies, prophylactic cranial irradiation (PCI) has been discussed as prevention for the development of brain metastasis in small-cell lung cancer. The results of these studies [45] [46] [47] [48] indicate that the frequency of cerebral seeding is reduced, but not prevented. The brain metastasis-free survival seems to be prolonged. Long-term ill effects of radiotherapy are usually not a significant issue in the treatment of brain metastases because of the short survival of the patients. Short-term effects are nausea, vomiting, headaches, alopecia, and in some cases fever. In longterm survivors ataxia, urinary incontinence, or even dementia might occur [49, 50] .
Radiosurgery
Many publications deal with the results of radiosurgery for single and multiple brain metastases [41, 42, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] . Stereotactic radiosurgery by gamma knife or linear accelerator is judged to be as effective as surgery. The applied doses range between 18 and 20 Gy. In 1987 Sturm et al. [61] described a shrinkage of metastases, reduction of cerebral edema and an improvement in clinical conditions in patients treated radiosurgically by linear accelerator. This was confirmed by others [42, 51] . The main domain for radiosurgery are small and deep-situated lesions that cannot be approached by surgery. However, the limitation for radiosurgery is size and number of lesions. Alexander et al. [54] reported on 248 patients with 421 lesions treated with a 6-Me V linear accelerator. Patients with a Karnofsky performance score less than 70, evidence of acute neurological deterioration, and tumors larger than 4 cm in diameter were excluded. The median treatment dose was 1,500 cGy. WBRT was applied in all newly diagnosed patients. The study [54] showed a median survival time of 9.4 months. Prolonged survival was observed in the absence of systemic disease, age younger than 60 years, maximally 2 cerebral lesions, and female sex. Actuarial local control rates were 85% at 1 year and 65% at 2 years. Factors associated with a significantly reduced local control rate were location below the tentorium and large tumor volume. The suitability of radiosurgery using the gamma knife was demonstrated by Kida et al. [53] . Cerebral metastases from primary tumors of different origin were treated with doses ranging from 12 to 25 Gy (mean 18.9 Gy). A tumor control rate of 98.2 and 96.6% was reported after 3 and 6 months, respectively. In a multiinstitutional U.S. study the outcome and prognostic factors subsequent to radiosurgery plus WBRT of single brain metastasis were evaluated [62] . Radiosurgery was performed with a linear accelerator applying a median dose of 17 Gy. In WBRT patients received a median dose of 37.5 Gy. 122 patients were treated. The overall local control rate was 86%; the actuarial median survival time after radiosurgery was 56 weeks. The influence of number of lesions on survival was emphasized by Joseph et al. [57] . Survival was equivalent for patients with 1 or 2 lesions to patients with a solitary metastasis treated by surgical resection and WBRT. Survival after radiosurgery for 3 or more lesions was similar to that reported for whole-brain irradiation. Radiosurgery versus surgery in terms of costs, hospitalization, morbidity, and wider applicability has been discussed by several authors [60, 63] . Since similar results are reported in radiosurgery and surgery, the cost effectiveness for radiosurgery seems to be more favorable. However, these considerations omit the fact that cerebral lesions should be classified by histology prior to radiotherapeutic treatment. Even if the primary tumor is known, cerebral lesions cannot be classified as metastases by MRI scan without any doubt [64] . Therefore, the patient has to undergo stereotactic biopsy, which mandates hospitalization at least for a short time. Both treatment modalities can be applied in lesions smaller than 3 cm in diameter, whereas in larger tumors only surgical extirpation is possible.
Treatment of Recurrent Brain Metastases
The final problem in treating brain metastases is the question of recurrent tumor growth. General opinion supports the decision for active treatment depending on the Karnofsky performance score of the patient, the extent of extracerebral metastases, and the interval of time between the last treatment and the recurrence of the lesions. Bindal et al. [65] evaluated 48 patients who developed recurrent brain metastases. Median survival time from first craniotomy to diagnosis of recurrence was 6.7 months. Median Karnofsky performance score prior to reoperation was 80. Median survival time after reoperation was 11.5 months. In a multivariate analysis, favorable prognostic factors were defined: no systemic disease, Karnofsky score above 70, time to recurrence more than 4 months, age above 40 years, primary tumor site with the exception of breast cancer and malignant melanoma. In cases of second recurrence, reoperation was considered. The median survival time averaged about 8.6 months versus 2.4 months for patients who did not undergo a second reoperation. These data were confirmed by Arbit et al. [66] when evaluating 109 patients with recurrent brain metastases of NSCLC. Sawaya et al. [37] stated that whenever possible surgery should remain the treatment of choice, even in recurrent brain metastases. Wong et al. [67] reported on 86 patients who were reirradiated for progressive brain metastases. All patients had received 30 Gy WBRT previously. The median dose of the second course was 20 Gy. The median survival time averaged about 4 months; in most cases neurological improvement occurred. The effectiveness of stereotactic radiosurgery for recurrent brain metastases has been investigated in many studies [41, 54, 68, 69] . Breneman et al. [41] treated 79 patients with recurrent tumor growth by radiosurgery. All of these patients had received WBRT before. The applied doses ranged between 16 and 18 Gy. The median survival for the entire group was 43 weeks from the date of radiosurgery and 71 weeks from the day of original diagnosis of brain metastases. This study and other extirpations [41, 57, 68] confirmed that patients with up to 2 cerebral metastases, but without active extracerebral tumor burden, showed prolonged survival time due to the applied treatment. In a study protocol of the Radiation Oncology Group, the effectiveness of radiosurgery was investigated with respect to tumor volume and recurrent cerebral metastases. A total of 102 patients were enrolled, of whom 64 had recurrent brain metastases and were irradiated prior with a dose of 30 Gy. Multivariate analysis revealed that a tumor volume of 8, 200 mm 3 or more is one of the limiting factors in treating patients with recurrent tumors by radiosurgery subsequent to previous irradiation [69] . Taken together, recurrent brain metastases can be approached either by surgery, radiosurgery, or second conventional radiotherapy. Depending on the Karnofsky performance scale, the extent of extracerebral tumor burden, and the time interval between the first cerebral metastasis and the recurrence (which should be more than 5 months), a decision must be made as to whether the patient will be treated surgically or not. Patients in good clinical conditions might profit from surgery. Radiosurgery offers an alternative treatment strategy. Even after previous radiotherapy, radiosurgery can be applied, although the risk for radiation-induced necrosis is increased. The expected median survival time for patients ranges from 6 to 12 months. In addition, a second course of conventional radiotherapy can be considered for some patients, since the routinely used dosage of 30 Gy allows for a second radiotherapy course.
Chemotherapy
Chemotherapy has its implication in the treatment of cerebral metastases. The tumor of origin determines the selection of chemotherapeutic agents. However, it has been shown that chemosensitivity from brain metastases can differ from the primary tumor [70] . The prerequisite for adjuvant chemotherapy is the maximal reduction of tumor burden by surgery. Many studies have been published with respect to chemotherapeutic trials of different carcinomas. Combined treatment strategiesradiotherapy and chemotherapy -are favored [71] [72] [73] [74] . One of the major points in advocating chemotherapy is the simultaneous treatment of cerebral metastases and extracerebral tumor burden. Since cancer is an ongoing disease in which cells constantly separate from tumor lesions and circulate in the bloodstream, the risk for metastatic seeding at different sites is high. Systemic involvement of the disease mandates systemic chemotherapy. The blood-brain barrier (BBB) does not allow the entrance of most of the chemotherapeutic agents into the brain [75] . Whereas lipophilic substances can penetrate the BBB easily, hydrophilic substances do not. In tumors the BBB is not totally intact. This is called blood-tumor barrier (BTB). The BTB allows the entrance of some additional chemotherapeutic agents, which normally do not gain access to the brain. Furthermore, opening of the BBB with hyperosmotic substances or bradykinine is possible [76, 77] . The complexity of cancer disease and chemotherapy demands the expertise of specialists.
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